CYP19A1 and breast cancer: Both compounds performed well in an international clinical trial [60], thereby validating Marco’s Model for the study of new antiestrogen agents or no estrogen (an aromatase inhibitor) to treat tamoxifen-resistant breast cancer patients successfully.